Koyfin Home > Directory > Health Care > Bristol-Myers Squibb Company > Long-Term Debt

Bristol-Myers Squibb Company Long-Term Debt Chart (BMY)

Bristol-Myers Squibb Company annual/quarterly Long-Term Debt from 2010 to 2020.
  • Bristol-Myers Squibb Company Long-Term Debt for the quarter ending September 09, 2020 was $41,365m a -4.89% decrease of -2,023m year over year
  • Bristol-Myers Squibb Company Long-Term Debt for the last 12 months ending September 09, 2020 was $41,365m a -4.89% decrease of -2,023m year over year
  • Bristol-Myers Squibb Company Annual Long-Term Debt for 2019 was $43,388m a 86.95% increase of 37,727m from 2018
  • Bristol-Myers Squibb Company Annual Long-Term Debt for 2018 was $5,661m a -23.21% decrease of -1,314m from 2017
  • Bristol-Myers Squibb Company Annual Long-Term Debt for 2017 was $6,975m a 18.05% increase of 1,259m from 2016
Other Cash Flow Metrics:
  • Bristol-Myers Squibb Company Cash Flow from Operations for the quarter ending September 09, 2018 was $1,279m a 12.67% increase of 162m year over year
  • Bristol-Myers Squibb Company Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $628m a -33.89% decrease of -213m year over year
  • Bristol-Myers Squibb Company Total Revenue for the quarter ending December 12, 2018 was $5,973m a 13.06% increase of 780m year over year
View Chart On Koyfin

Quarterly BMY Long-Term Debt Data

09/2020$41,365m
06/2020$41,853m
03/2020$42,844m
12/2019$43,388m
09/2019$24,392m
06/2019$24,433m
03/2019$5,635m
12/2018$5,661m
09/2018$5,687m
06/2018$5,671m

Annual BMY Long-Term Debt Data

2019$43,388m
2018$5,661m
2017$6,975m
2016$5,716m
2015$6,558m
2014$7,245m
2013$8,008m
2012$6,568m
2011$5,376m
2010$5,328m